Zevra Therapeutics (ZVRA) Cost of Revenue (2019 - 2026)

Zevra Therapeutics (ZVRA) has 7 years of Cost of Revenue data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Cost of Revenue rose 41.04% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 98.37% YoY) and the FY2025 annual result came in at $16.5 million, up 122.22% from the prior year.
• Cost of Revenue rose to $1.9 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $12.4 million in Q2 2025 to a low of $8000.0 in Q1 2022.
• A 5-year average of $1.7 million and a median of $1.2 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue tumbled 98.0% — and 2023, when it surged 3285.0%.
• Tracing ZVRA's Cost of Revenue over 5 years: stood at $92000.0 in 2022, then jumped by 1233.7% to $1.2 million in 2023, then climbed by 11.33% to $1.4 million in 2024, then climbed by 11.27% to $1.5 million in 2025, then climbed by 24.8% to $1.9 million in 2026.
• The last three Cost of Revenue figures came in at $1.9 million (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.